SCRI’s contract research organization: the premier partner of choice
The contract research organization (CRO) model of today requires an ever-evolving approach to address increasing demands – from FDA requirements for diversity plans for clinical trial participation to growing requests for supporting efficient clinical trial design and the availability of high-quality data for rapid analysis – all while maintaining the goal of producing clinically meaningful results.
Learn about how SCRI Development Innovations is uniquely positioned to make an impact.
Optimizing the CRO model to address the industry’s ever-changing landscape
SCRI Development Innovations, our global, full-service CRO, offers end-to-end capabilities fully dedicated to oncology – from first-in-human studies to regulatory approval. Our patients are at the center of every decision we make. We have a long history and proven track record of partnering with biopharma companies to design, manage and monitor Phase 1 through Phase 4 clinical trials and analyze the results to advance therapies for people facing cancer.
SCRI Development Innovations leverages the expertise of globally recognized oncologists to design and implement clinical trials.
Through Accelero, we work in tandem with our centralized Site Management Organization (SMO) to design and deliver timely site activation, patient recruitment and overall study delivery. This enhanced collaboration enables efficiencies that accelerate drug development and optimize clinical trial operations.
Our Personalized Medicine program, powered by precision medicine technology from Genospace, offers scientific consultative services to our biopharma partners to inform clinical development approaches every step of the way and enrich clinical development insights.
We have been providing CRO services in oncology since 2006.
Our roots are in cancer. With our network of affiliated community-based clinical trial sites at more than 250 locations in 24 states in the U.S. with more than 1,300 research physicians enrolling patients in clinical trials, we are able to leverage our existing strategic relationships and infrastructure to expedite the start-up of clinical trials in as few as six weeks. We also have unique capabilities in personalized medicine and data.
Proven performance
- 395+ trials conducted to date, including both industry-sponsored and investigator-initiated trials
- 70+ first-in-human trials conducted
- 25+ first-in-class trials conducted
Optimizing the CRO model to address the industry’s ever-changing landscape
SCRI Development Innovations, our global, full-service CRO, offers end-to-end capabilities fully dedicated to oncology – from first-in-human studies to regulatory approval. Our patients are at the center of every decision we make. We have a long history and proven track record of partnering with biopharma companies to design, manage and monitor Phase 1 through Phase 4 clinical trials and analyze the results to advance therapies for people facing cancer.
SCRI Development Innovations leverages the expertise of globally recognized oncologists to design and implement clinical trials.
Through Accelero, we work in tandem with our centralized Site Management Organization (SMO) to design and deliver timely site activation, patient recruitment and overall study delivery. This enhanced collaboration enables efficiencies that accelerate drug development and optimize clinical trial operations.
Our Personalized Medicine program, powered by precision medicine technology from Genospace, offers scientific consultative services to our biopharma partners to inform clinical development approaches every step of the way and enrich clinical development insights.
We have been providing CRO services in oncology since 2006.
Our roots are in cancer. With our network of affiliated community-based clinical trial sites at more than 250 locations in 24 states in the U.S. with more than 1,300 research physicians enrolling patients in clinical trials, we are able to leverage our existing strategic relationships and infrastructure to expedite the start-up of clinical trials in as few as six weeks. We also have unique capabilities in personalized medicine and data.
Proven performance
- 395+ trials conducted to date, including both industry-sponsored and investigator-initiated trials
- 70+ first-in-human trials conducted
- 25+ first-in-class trials conducted